Receptor Interacting Ser/Thr-Protein Kinase 2 as a New Therapeutic Target-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Receptor Interacting Ser/Thr-Protein Kinase 2 as a New Therapeutic Target

Published:2023-10-19 Issue:21 Volume:66 Page:14391-14410
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Rivoal Morgane¹,Dubuquoy Laurent¹^ORCID,Millet Régis¹,Leleu-Chavain Natascha¹^ORCID

Affiliation:

1. Inserm, U1286 − INFINITE − Institute for Translational Research in Inflammation, University of Lille, F-59000 Lille, France

Funder

Région Hauts-de-France

Ecole doctorale Biologie Santé de Lille

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c00593

Reference132 articles.

1. FDA-approved small-molecule kinase inhibitors

2. RIPK protein kinase family: Atypical lives of typical kinases

3. The RIP kinases: crucial integrators of cellular stress

4. Involvement of receptor-interacting protein 2 in innate and adaptive immune responses

5. Identification of a regulatory autophosphorylation site in the serine–threonine kinase RIP2

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NOD1 and NOD2: Essential Monitoring Partners in the Innate Immune System;Current Issues in Molecular Biology;2024-08-28

2. RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development;European Journal of Medicinal Chemistry;2024-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP